Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

2.

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults.

International Collaboration on HIV and Cancer..

J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30.

PMID:
11078759
3.

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.

Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Porter K, Walker AS; CASCADE Collaboration..

Lancet. 2003 Oct 18;362(9392):1267-74.

PMID:
14575971
4.

Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.

Dorrucci M, Pezzotti P, Phillips AN, Alliegro MB, Rezza G.

AIDS. 1997 Mar 15;11(4):461-7.

PMID:
9084793
6.

[Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].

Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G; l'Italian Seroconversion Study..

Epidemiol Prev. 2003 Nov-Dec;27(6):348-55. Italian.

PMID:
15058363
7.

AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters.

Biggar RJ.

AIDS. 1990 Nov;4(11):1059-66. Erratum in: AIDS 1991 Feb;5(2):245.

PMID:
2282177
8.

Estimating the effect of antiretroviral treatment during HIV seroconversion: impact of confounding in observational data.

Clements M, Law M, Pedersen C, Kaldor J; CASCADE Collaboration..

HIV Med. 2003 Oct;4(4):332-7.

9.

Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study.

Rezza G.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17 Suppl 1:S13-6.

PMID:
9586645
10.

Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

Concerted Action on SeroConversion to AIDS and Death in Europe (CASCADE Collaboration)..

J Acquir Immune Defic Syndr. 2001 Oct 1;28(2):158-65.

PMID:
11588510
11.

Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.

CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration..

HIV Med. 2000 Oct;1(4):224-31.

12.

HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?

Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, Whitworth JA.

AIDS. 2002 Mar 8;16(4):597-603.

PMID:
11873003
13.

Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.

Detels R, Muñoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrager LK, Phair JP.

JAMA. 1998 Nov 4;280(17):1497-503.

PMID:
9809730
14.

Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion.

Touloumi G, Karafoulidou A, Gialeraki A, Katsarou O, Milona I, Kapsimali V, Mandalaki T, Hatzakis A.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Sep 1;19(1):89-97.

PMID:
9732075
15.

Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study.

Rezza G, Dorrucci M, Serraino D, Andreoni M, Giuliani M, Zerboni R, Sarmati L, Colangeli V, Salassa B, Monini P, Ensoli B, Pezzotti P.

AIDS. 2000 Jul 28;14(11):1647-53.

PMID:
10983652
16.
17.

Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration..

J Natl Cancer Inst. 2010 Jun 2;102(11):784-92. doi: 10.1093/jnci/djq134. Epub 2010 May 4.

18.

Is AIDS a floating point between HIV seroconversion and death? Insights from the Tricontinental Seroconverter Study.

van Benthem BH, Veugelers PJ, Cornelisse PG, Strathdee SA, Kaldor JM, Shafer KA, Coutinho RA, van Griensven GJ.

AIDS. 1998 Jun 18;12(9):1039-45.

PMID:
9662201
19.

The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis.

Hendriks JC, Satten GA, van Ameijden EJ, van Druten HA, Coutinho RA, van Griensven GJ.

AIDS. 1998 Aug 20;12(12):1537-44.

PMID:
9727576
20.

Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics.

May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA; Antiretroviral Therapy Cohort Collaboration (ART-CC)..

Int J Epidemiol. 2012 Dec;41(6):1807-20. doi: 10.1093/ije/dys164. Epub 2012 Nov 12.

Supplemental Content

Support Center